中国北京门诊患者中，灭活 COVID-19 疫苗对奥密克戎变异株 BF.7 的有效性。

Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients in Beijing, China.

机构信息

Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.

Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Clinical Pharmacy, School of Pharmaceutical Science, Capital Medical University, Beijing 100069, China.

出版信息

Vaccine. 2023 Nov 22;41(48):7201-7205. doi: 10.1016/j.vaccine.2023.10.036. Epub 2023 Oct 17.

DOI:10.1016/j.vaccine.2023.10.036

PMID:37852869

Abstract

OBJECTIVE

To evaluate the effectiveness of inactivated vaccines against SARS-CoV-2 Omicron subvariant BF.7.

METHODS

Information was extracted from outpatients diagnosed with COVID-19 between December 19, 2022 and January 5, 2023 at a single center. Univariate and multivariate logistic regression were performed and three adjusted models were conducted. Vaccine effectiveness (VE) was defined as (1 - OR) × 100 %.

RESULTS

Our study comprised a total of 752 outpatients. After adjusting for factors with a P-value < 0.10 in univariable logistic regression, the VE of booster vaccine was 65.4 % (95 % CI6.1-87.3 %, P = 0.037) in comparison with unvaccinated group. Results of the other two adjusted models were similar, which were 66.3 % (95 % CI: 9.0-87.6 %, P = 0.032) and 64.8 % (95 % CI: 3.6-87.1 %, P = 0.042), respectively. Stratified analysis based on underlying diseases indicated that inactivated vaccines did not provide any protection to patients without underlying diseases. In the population with underlying diseases, the VE of booster vaccination was 68.2 % (95 % CI: 8.4-88.9 %, P = 0.034) after adjustment. However, full vaccination did not demonstrate any protection in all models.

CONCLUSION

There was an effectiveness of three-dose inactivated vaccines against Omicron subvariant BF.7. Our findings supported the importance of booster vaccination.

摘要

目的

评估针对 SARS-CoV-2 奥密克戎变异株 BF.7 的灭活疫苗的有效性。

方法

本研究从 2022 年 12 月 19 日至 2023 年 1 月 5 日期间在一家单中心就诊的确诊 COVID-19 的门诊患者中提取信息。进行单变量和多变量逻辑回归分析，并构建了三个调整模型。疫苗有效性（VE）定义为（1-OR）×100%。

结果

本研究共纳入了 752 名门诊患者。在单变量逻辑回归分析中 P 值<0.10 的因素进行调整后，与未接种组相比，加强针疫苗的 VE 为 65.4%（95%CI6.1-87.3%，P=0.037）。另外两个调整模型的结果也相似，分别为 66.3%（95%CI：9.0-87.6%，P=0.032）和 64.8%（95%CI：3.6-87.1%，P=0.042）。基于基础疾病的分层分析表明，灭活疫苗对无基础疾病的患者没有提供任何保护。在有基础疾病的人群中，加强针接种的 VE 在调整后为 68.2%（95%CI：8.4-88.9%，P=0.034）。然而，在所有模型中，全剂量疫苗接种均未显示出任何保护作用。